Please select the eligibility criteria that correspond to the clinical trial below.
Title: PPAR Alpha: A Phase 2 Dose-Finding and Safety Study for Atherogenic Dyslipidemia by Eli Lilly
Brief Summary: The purposes of this study are to determine:

* The safety of the study medication and any side effects that might be associated with it;
* Whether the study medication can help patients with low levels of 'good' cholesterol (HDL-C) and high blood fats or triglycerides (TG);
* How much of the study medication should be given to patients;
* How the study medication compares to fenofibrate (Lofibra), a drug used for people with low levels of HDL-C and high levels of TG.


Options:
A: Inclusion Criteria:

* Holter monitoring at baseline which demonstrates a total of 15 minutes of ischemia and/or 3 ischemic events per 48 hours.
* Total cholesterol \> 5.2 mmol/L (200 mg/dL) on diet alone.

Exclusion Criteria:

* Myocardial infarction within 2 months prior to the study.
* Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol.
B: Inclusion Criteria:

* Age≥18 years old
* LVEF ≤ 35%, as documented by echocardiography, radionuclide ventriculography, gated SPECT, or contrast ventriculography within past 6 months
* Symptomatic HF (NYHA II-IV) or current NYHA I with history of symptomatic HF within the last year
* Stable doses of optimal HF medical therapy, unless documented contraindication.

Exclusion Criteria:

* Ischemic etiology of HF, defined as the presence of at least one of the following four criteria; angiographic evidence of \> 50% lesion in 1 or more of the 3 major epicardial vessels; history of myocardial infarction; history of revascularization procedure; evidence of significant perfusion defect in the setting of ischemic symptoms.
* Clinical indication for statin treatment - coronary artery, cerebrovascular, or peripheral vascular disease
* Major cardiovascular event or surgical procedure within past 8 weeks
* LDL\<70 mg/dL
* HF secondary to congenital heart disease or uncorrected valvular disease
* Treatment with statin within past 2 months
* Pregnancy
* Contraindication to statin: moderate liver disease, AST/ALT \> 150 U/ L, known hypersensitivity
* Likely to receive heart transplant within 3 months
* Known peripheral or autonomic neuropathy
C: Inclusion Criteria:

* Meets American College of Rheumatology (ACR) revised diagnostic guidelines for SLE
* Weight of 25 kg (55 lbs) or more
* Outpatient
* Ability to complete self-report questionnaires in either English or Spanish
* Willingness to comply with recommended diet
* Acceptable methods of contraception

Exclusion Criteria:

* Drug-induced lupus
* Liver disease (ALT or aspartate aminotransferase greater than 2 X normal value)
* Myositis (CK greater than 3 X normal value)
* Inability to obtain adequate-quality IMT images
* Current use of oral or parenteral tacrolimus or cyclosporine
* Dialysis or serum creatinine reater than 2.5 mg/dL
* Active nephrotic syndrome (urinary protein greater than 3 g/24 h and serum albumin less than 2.3 g/dl)
* Total cholesterol greater than 350 mg/dL
* Xanthoma
* Familial hypercholesterolemia
* Pregnant or breastfeeding
* Use of estrogen-containing contraceptives (e.g., Lo-Ovral)
* Unable to adhere to study regimen
* Life-threatening non-SLE illness that would interfere with ability to complete the study
* Current drug or alcohol abuse
* Anticipated poor compliance
* Participation in another drug intervention study within 30 days of study enrollment
D: Inclusion Criteria:

* Men and women between 18 and 80 years of age
* People with abnormal fat levels in the blood (low HDL, high TG)

Exclusion Criteria:

* People with diabetes
* People whose blood pressure is greater than 160/95 mm Hg, on or off blood pressure medicine
* People who have had frequent chest pain or unstable angina, a heart attack or a heart procedure, including stent placement, within the past 3 months

Answer: D